Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableApproved For MarketingNCT05463939
What this trial is testing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Not applicableUnknownNCT06354595
What this trial is testing

Feasibility Study of Multidimensional Rehabilitation in the Metaverse

Who this might be right for
Colorectal Neoplasms
Qu Shen 10
Testing effectiveness (Phase 2)Study completedNCT00081939
What this trial is testing

UARK 2003-33, Total Therapy III

Who this might be right for
Multiple Myeloma
University of Arkansas 303
Large-scale testing (Phase 3)Active Not RecruitingNCT04934475
What this trial is testing

MInimal Residual Disease Adapted Strategy

Who this might be right for
Multiple Myeloma
Intergroupe Francophone du Myelome 791
Testing effectiveness (Phase 2)Looking for participantsNCT06892522
What this trial is testing

Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Who this might be right for
Multiple Myeloma
AbbVie 602
Testing effectiveness (Phase 2)Looking for participantsNCT04661137
What this trial is testing

Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 96
Early research (Phase 1)Study completedNCT05024045
What this trial is testing

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-cell Marginal ZoneLymphoma, Non-Hodgkin+4 more
Eli Lilly and Company 27
Testing effectiveness (Phase 2)Study completedNCT02192775
What this trial is testing

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

Who this might be right for
Multiple Myeloma
University of Arkansas 2
Testing effectiveness (Phase 2)UnknownNCT01965275
What this trial is testing

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Who this might be right for
Self EfficacyDrug Toxicity
Anhui Medical University 20
Testing effectiveness (Phase 2)Looking for participantsNCT04414475
What this trial is testing

Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Who this might be right for
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc 127
Not applicableLooking for participantsNCT06536257
What this trial is testing

Personalised Immunotherapy Platform

Who this might be right for
MelanomaCutaneous Squamous Cell CarcinomaBasal Cell Carcinoma+2 more
Melanoma Institute Australia 1,000
Not applicableUnknownNCT05816629
What this trial is testing

Multiparameter Ultrasound Based-AI for the Diagnosis of Thyroid Nodules

Who this might be right for
Thyroid Nodule
Second Affiliated Hospital, Zhejiang University, School of Medicine 2,000
Testing effectiveness (Phase 2)WithdrawnNCT01055301
What this trial is testing

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple MyelomaPlasma Cell Myeloma
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00040872
What this trial is testing

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Study completedNCT00674739
What this trial is testing

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Who this might be right for
Genital Warts
Graceway Pharmaceuticals, LLC 470
Not applicableUnknownNCT04034953
What this trial is testing

Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong

Who this might be right for
ObesityColorectal CancerProstate Cancer+1 more
Chinese University of Hong Kong 10,000
Not applicableEnded earlyNCT04561453
What this trial is testing

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerCholangiocarcinomaGallbladder Cancer+5 more
University of Washington 14
Large-scale testing (Phase 3)Study completedNCT04693637
What this trial is testing

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Who this might be right for
Adenovirus InfectionBK Virus InfectionCytomegalovirus Infections+3 more
AlloVir 26
Testing effectiveness (Phase 2)Looking for participantsNCT07032129
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma Progression+1 more
Essen Biotech 60
Not applicableLooking for participantsNCT06181331
What this trial is testing

The Effect of a Stepped-care Metacognition-based Intervention on Managing Fear of Cancer Recurrence

Who this might be right for
CancerFear of Cancer Recurrence
The University of Hong Kong 300
Next Page